Softox with “potential breakthrough” in the crown battle – E24

Softox Solutions’ share increased more than 40 percent after the company submitted an update on the inhalation study the company is conducting on small pigs.

Study results show “very promising results” with a view to developing the company’s technology for treating respiratory infections, including corona patients, the company writes.

– With our smooth and efficient technology, we now have the opportunity to plan the first human studies (phase I). Unlike many other treatments, our treatment is directly aimed at inactivating the coronavirus, says Softox CEO Geir Almås in a statement.

To obtain advice on the further development path of such a medicine, the company has arranged a meeting with the Danish Medicines Agency (Lægemiddelstyrelsen).

– We are optimistic about achieving a faster path for patients with a “fast track” recommendation, says Medical Director Glenn Gundersen.

Softox stock has fallen slightly from the top and is trading at 2.20pm with a rise of 31.43 percent to 69 kroner. So far this year, the stock is up more than 100 percent.

In late March, Softox issued two announcements that it had decided to co-finance a research team at the University of Copenhagen to begin work on seeing the effect of the company’s inhalation technology to counteract viral and bacterial infections in the respiratory tract and lungs.

The company allocated DKK 2.5 million to the project, which was scheduled to last six months.

– We have analyzed the effect of the SoftOx solution on the respiratory tract and this may be the solution the world is waiting for, which can play an important role in treating current and future epidemics and pandemics, says Professor of Bacteriology Thomas Bjarnsholt in the University of Copenhagen and Rigshospitalet in Copenhagen in a comment.

Notably, Bjarnsholt is associated with the company as a member of the Softox Scientific Advisory Board. He also has regular assignments as a consultant to the company.